---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-298052"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2022-12-05T23:59:59+00:00"
generated_at: "2026-06-21T09:31:10.320051+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Karyopharm raises $165M in PIPE; sells 31.8M shares at $5.19 with warrants

## Summary
- Gross proceeds ~$165M from sale of 31,791,908 shares at $5.19 and warrants for 9,537,563 shares at $6.36.
- Lead investors include Avidity Partners, Adage Capital, Armistice Capital, and others; expected close Dec 7, 2022.
- Proceeds to fund selinexor and eltanexor clinical programs, working capital; cash runway extended into late 2025.
- Warrants exercisable for five years after closing; registration statement for resale to be filed within 30 days.

## SEC filing metadata
- accession: 0001193125-22-298052
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2022-12-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000119312522298052/0001193125-22-298052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000119312522298052/d418804d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-298052
- JSON: https://secwatch.observer/filing/0001193125-22-298052.json
- Plain text: https://secwatch.observer/filing/0001193125-22-298052.txt

## Key facts
- Material Agreements
  Karyopharm Therapeutics Inc. entered into Securities Purchase Agreement with certain institutional investors valued at approximately $165 million (effective 2022-12-05).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors
  - Value: approximately $165 million
  - Effective: 2022-12-05
  source text: On December 5, 2022, Karyopharm Therapeutics Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain institutional investors (the “ Purchasers ”), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement an aggregate of (i) 31,791,908 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) and (ii) accompanying warrants (the “ Warrants ”) to purchase up to 9,537,563 shares of Common Stock (collectively, the “ Private Placement ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1503802/000119312522298052/0001193125-22-298052-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.